Enhances B Cell Responses in Type 2 Inflammation Through IL-17RB Receptor,” published in the January 2025 issue of Allergy ...

Nasal polyps are fleshy swellings that develop in the lining of the nose and paranasal sinuses, which are the air-filled spaces linked to the nasal cavity. They are noncancerous growths.

Low vitamin D in patients with nasal polyps negatively correlated with several markers, including Lund-Mackay and total nasal ...

What you may think are allergies or a cold, could be the sign of nasal polyps. Nasal polyps are non-cancerous growths that line the nasal passages and sinuses. They are soft, painless, and hang ...

But if your kitty’s stuffy nose persists, it may be time to consider other causes, including nasal polyps in cats. Feline nasal polyps can cause similar symptoms to the common cat cold.

Nasal polyps can be a persistent issue for individuals suffering from chronic sinusitis, allergies, or fungal infections, often leading to breathing difficulties and discomfort. When medications ...

The key to their discovery was finding granzyme K and the memory CD8+ T cells that produce it as important factors causing relapses in stubborn chronic rhinosinusitis with nasal polyps. These could ...

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with nasal ...

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

Researchers identify a pathogenic subset of CD8+ memory T-cells that promote airway tissue inflammation and recurrent ...

GSK plc announced that the China National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on therapy with ...

According to Future Market Insights, the global nasal allergy treatment market is poised for substantial growth, with its valuation expected to double from USD 6.6 billion in 2022 to USD 13.3 billion ...